Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
aTyr Pharma logo — aTyr is a biotherapeutics company engaged in the development...

aTyr Pharma

aTyr is a biotherapeutics company engaged in the development of innovative medicines based on novel biology.

Founded 2005 United States San Diego, United States 79 employees Post Ipo Equity Total: $402.50M Biotechnology, Health and Wellness +1

General Information

Company Name aTyr Pharma
Founded Year 2005
Location United States San Diego, United States +2
Founders / Decision Makers
Team member Team member
Employees 79
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when aTyr Pharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About aTyr Pharma

aTyr Pharma is a biotherapeutics company that is focused on developing innovative medicines based on novel biology. The company, listed on Nasdaq under the symbol LIFE, is dedicated to the discovery and development of medicines based on novel biological pathways, particularly the extracellular functionality and signaling pathways of tRNA synthetases. With a robust global intellectual property estate, aTyr Pharma has directed its efforts towards a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. The company's primary focus is on their clinical-stage product candidate efzofitimod (ATYR1923), designed to bind to the neuropilin-2 receptor and down-regulate immune engagement in severe inflammatory lung diseases. The company was founded in 2005 by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., who are leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. In a recent development, aTyr Pharma secured a $50.00M Post-IPO Equity investment on 08 February 2023. For more information about the company, please visit http://www.atyrpharma.com. With its innovative approach to drug development, aTyr Pharma presents an exciting opportunity for investors looking to be part of cutting-edge advancements in the biotechnology and pharmaceutical industries.

Taxonomy: Biotherapeutics, Drug discovery, Biologics, Immunomodulation, Rare diseases, Orphan diseases, Autoimmune diseases, Protein biologics, Inflammatory lung diseases, Extracellular pathways, tRNA synthetases, Neuropilin-2 receptor, Preclinical development, Intellectual property, Life sciences

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 08 Feb 2023
Post-IPO Equity •••••• - 15 Sep 2021
Post-IPO Equity •••••• - 10 Mar 2020
Post-IPO Equity •••••• 3
Investor Investor Investor
28 Aug 2017
Post-IPO Debt •••••• 2 •••• •••• 21 Nov 2016

View All 11 Funding Rounds

aTyr Pharma Alternatives & Competitors

aTyr Pharma vs
Surrozen
Surrozen United States

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicin...

Unknown
67 employees
Biotechnology, Health Care
Compare aTyr Pharma vs Surrozen
aTyr Pharma vs
ILIAS Biologics Inc.
ILIAS Biologics Inc. Korea South

The Global Leader in Exosome-based Therapeutics

Series B
18 employees
Biopharma, Biotechnology
Compare aTyr Pharma vs ILIAS Biologics Inc.
aTyr Pharma vs
Imeka
Imeka Canada

We specialize in brain imaging specifically white matter, neuroinflammation, free-water and more. Im...

Unknown
22 employees
AI, Biotechnology
Compare aTyr Pharma vs Imeka

FAQ About aTyr Pharma

aTyr is a biotherapeutics company engaged in the development of innovative medicines based on novel biology.
aTyr Pharma was founded in 2005.
aTyr Pharma is headquartered in San Diego, United States.
aTyr Pharma operates in the following industries: Biotechnology, Health and Wellness, Pharmaceutical.
aTyr Pharma has approximately 79 employees.
aTyr Pharma has completed 11 funding rounds, raising a total of $402.50M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to aTyr Pharma include Surrozen, ILIAS Biologics Inc., Imeka, Tandem Therapeutics, AsclepiX Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
aTyr Pharma and Surrozen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors aTyr Pharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes